On the public citation graph

An Open-Label, Randomized Phase III Study of Telpegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer

0 signed · 27 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s00520-014-2457-zopenalex-extracted
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
inferredcites →https://doi.org/10.1007/s00520-014-2555-yopenalex-extracted
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer
inferredcites →https://doi.org/10.1007/s10549-017-4609-6openalex-extracted
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
inferredcites →https://doi.org/10.1007/s12272-021-01312-yopenalex-extracted
Mechanisms of resistance to chemotherapy in non-small cell lung cancer
inferredcites →https://doi.org/10.1016/j.cllc.2015.12.002openalex-extracted
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)
inferredcites →https://doi.org/10.1016/j.ejca.2010.10.013openalex-extracted
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
inferredcites →https://doi.org/10.1016/j.jncc.2022.02.002openalex-extracted
Cancer incidence and mortality in China, 2016
inferredcites →https://doi.org/10.1093/annonc/mdg019openalex-extracted
A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
inferredcites →https://doi.org/10.1093/annonc/mdt226openalex-extracted
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
inferredcites →https://doi.org/10.1097/cad.0b013e3283610b5dopenalex-extracted
Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens
inferredcites →https://doi.org/10.1111/1759-7714.14233openalex-extracted
Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony‐stimulating factor as support to chemotherapy for lung cancer
inferredcites →https://doi.org/10.1111/1759-7714.14544openalex-extracted
PEG‐rhG‐CSF for prophylaxis of neutropenia after chemotherapy in patients with non–small cell lung cancer: A multicenter, prospective, randomized study
inferredcites →https://doi.org/10.1111/bcp.15507openalex-extracted
A prospective, randomized clinical trial of emergency treatment of chemotherapy‐induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF)
inferredcites →https://doi.org/10.1159/000345626openalex-extracted
Prevention of Chemotherapy-Induced Neutropenia with Pegfilgrastim: Pharmacokinetics and Patient Outcomes
inferredcites →https://doi.org/10.1186/s12885-021-08258-wopenalex-extracted
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety
inferredcites →https://doi.org/10.1200/jco.2000.18.10.2095openalex-extracted
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
inferredcites →https://doi.org/10.1200/jco.2000.18.12.2354openalex-extracted
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
inferredcites →https://doi.org/10.1200/jco.2003.12.046openalex-extracted
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
inferredcites →https://doi.org/10.1200/jco.2004.08.163openalex-extracted
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
inferredcites →https://doi.org/10.1200/jco.2005.09.102openalex-extracted
First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
inferredcites →https://doi.org/10.1200/jco.2006.06.4451openalex-extracted
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
inferredcites →https://doi.org/10.1200/jco.2015.64.8824openalex-extracted
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.18632/oncotarget.18145openalex-extracted
Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients
inferredcites →https://doi.org/10.20892/j.issn.2095-3941.2020.0069openalex-extracted
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges
inferredcites →https://doi.org/10.21147/j.issn.1000-9604.2017.05.04openalex-extracted
A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia
inferredcites →https://doi.org/10.3389/fbioe.2020.572077openalex-extracted
Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity
inferredcites →https://doi.org/10.3816/ccc.2010.n.013openalex-extracted
A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.